Log in

NYSE:NVO - Novo Nordisk A/S Stock Price, Forecast & News

$56.73
-0.03 (-0.05 %)
(As of 03/29/2020 05:54 AM ET)
Today's Range
$55.01
Now: $56.73
$57.63
50-Day Range
$49.46
MA: $59.44
$64.78
52-Week Range
$46.47
Now: $56.73
$64.82
Volume2.38 million shs
Average Volume3.04 million shs
Market Capitalization$134.34 billion
P/E Ratio23.06
Dividend Yield1.12%
Beta0.6
Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company has a strategic alliance with Evotec AG to discover and develop small molecule therapies to treat patients suffering from diabetes, obesity, and co-morbidities, as well as has a research collaboration with Kallyope Inc. It also has a collaboration agreement Lund University to develop stem cell-derived treatment for Parkinson's diseases; and Staten Biotechnology B.V. to develop novel therapeutics for the treatment of dyslipidaemia. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark.
Read More
Novo Nordisk A/S logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone45-4444-8888

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$18.30 billion
Cash Flow$2.82 per share
Book Value$3.65 per share

Profitability

Net Income$5.84 billion

Miscellaneous

Employees43,258
Outstanding Shares2,368,000,000
Market Cap$134.34 billion
Next Earnings Date5/1/2020 (Estimated)
OptionableOptionable

Receive NVO News and Ratings via Email

Sign-up to receive the latest news and ratings for NVO and its competitors with MarketBeat's FREE daily newsletter.


Novo Nordisk A/S (NYSE:NVO) Frequently Asked Questions

How has Novo Nordisk A/S's stock been impacted by COVID-19 (Coronavirus)?

Novo Nordisk A/S's stock was trading at $57.89 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NVO shares have decreased by 2.0% and is now trading at $56.73. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Novo Nordisk A/S?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novo Nordisk A/S in the last year. There are currently 1 sell rating, 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Novo Nordisk A/S.

When is Novo Nordisk A/S's next earnings date?

Novo Nordisk A/S is scheduled to release its next quarterly earnings announcement on Friday, May 1st 2020. View our earnings forecast for Novo Nordisk A/S.

How were Novo Nordisk A/S's earnings last quarter?

Novo Nordisk A/S (NYSE:NVO) announced its quarterly earnings data on Wednesday, February, 5th. The company reported $0.55 EPS for the quarter, hitting the consensus estimate of $0.55. The business earned $4.80 billion during the quarter, compared to analysts' expectations of $4.83 billion. Novo Nordisk A/S had a net margin of 31.95% and a return on equity of 73.70%. View Novo Nordisk A/S's earnings history.

How often does Novo Nordisk A/S pay dividends? What is the dividend yield for Novo Nordisk A/S?

Novo Nordisk A/S announced a semi-annual dividend on Friday, February 7th. Stockholders of record on Monday, March 30th will be given a dividend of $0.7874 per share on Tuesday, April 7th. This represents a yield of 1.4%. The ex-dividend date is Friday, March 27th. This is a boost from Novo Nordisk A/S's previous semi-annual dividend of $0.32. View Novo Nordisk A/S's dividend history.

What guidance has Novo Nordisk A/S issued on next quarter's earnings?

Novo Nordisk A/S updated its FY 2020 IntraDay earnings guidance on Wednesday, February, 5th. The company provided EPS guidance of for the period. The company issued revenue guidance of $18.852-19.401 billion, compared to the consensus revenue estimate of $18.74 billion.

What price target have analysts set for NVO?

9 brokerages have issued twelve-month target prices for Novo Nordisk A/S's shares. Their forecasts range from $51.85 to $400.00. On average, they anticipate Novo Nordisk A/S's stock price to reach $214.82 in the next year. This suggests a possible upside of 278.7% from the stock's current price. View analysts' price targets for Novo Nordisk A/S.

Has Novo Nordisk A/S been receiving favorable news coverage?

Media headlines about NVO stock have trended somewhat positive this week, according to InfoTrie. The research group rates the sentiment of news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Novo Nordisk A/S earned a media sentiment score of 1.2 on InfoTrie's scale. They also assigned news articles about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next few days. View the latest news aboutNovo Nordisk A/S.

Are investors shorting Novo Nordisk A/S?

Novo Nordisk A/S saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 5,108,900 shares, an increase of 9.9% from the February 27th total of 4,650,000 shares. Based on an average daily trading volume, of 1,500,000 shares, the days-to-cover ratio is presently 3.4 days. Approximately 0.4% of the shares of the stock are sold short. View Novo Nordisk A/S's Current Options Chain.

Who are some of Novo Nordisk A/S's key competitors?

What other stocks do shareholders of Novo Nordisk A/S own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Novo Nordisk A/S investors own include Gilead Sciences (GILD), AbbVie (ABBV), Pfizer (PFE), NVIDIA (NVDA), Johnson & Johnson (JNJ), AT&T (T), QUALCOMM (QCOM), Starbucks (SBUX), Alibaba Group (BABA) and Walt Disney (DIS).

Who are Novo Nordisk A/S's key executives?

Novo Nordisk A/S's management team includes the following people:
  • Mr. Lars Fruergaard Jørgensen, Pres & CEO (Age 53)
  • Dr. Mads Krogsgaard Thomsen, Exec. VP & Chief Science Officer (Age 59)
  • Mr. Karsten Munk Knudsen, Exec. VP & CFO (Age 47)
  • Mr. Lars Green, Exec. VP and Head of Bus. Services & Compliance (Age 52)
  • Mr. Ole F. Ramsby, Sr. VP & Gen. Counsel of Legal Affairs

What is Novo Nordisk A/S's stock symbol?

Novo Nordisk A/S trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVO."

Who are Novo Nordisk A/S's major shareholders?

Novo Nordisk A/S's stock is owned by a variety of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (1.11%), Loomis Sayles & Co. L P (0.92%), Bank of America Corp DE (0.48%), State Street Corp (0.19%), Everett Harris & Co. CA (0.13%) and Sustainable Growth Advisers LP (0.11%). View institutional ownership trends for Novo Nordisk A/S.

Which major investors are selling Novo Nordisk A/S stock?

NVO stock was sold by a variety of institutional investors in the last quarter, including Sustainable Growth Advisers LP, Bank of America Corp DE, State Street Corp, NorthCoast Asset Management LLC, Credit Suisse AG, Alyeska Investment Group L.P., Hikari Power Ltd, and Boston Partners. View insider buying and selling activity for Novo Nordisk A/S.

Which major investors are buying Novo Nordisk A/S stock?

NVO stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, First Trust Advisors LP, Loomis Sayles & Co. L P, Capital International Investors, Amundi Pioneer Asset Management Inc., Bain Capital Public Equity Management II LLC, Connor Clark & Lunn Investment Management Ltd., and Beacon Investment Advisory Services Inc.. View insider buying and selling activity for Novo Nordisk A/S.

How do I buy shares of Novo Nordisk A/S?

Shares of NVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Novo Nordisk A/S's stock price today?

One share of NVO stock can currently be purchased for approximately $56.73.

How big of a company is Novo Nordisk A/S?

Novo Nordisk A/S has a market capitalization of $134.34 billion and generates $18.30 billion in revenue each year. The company earns $5.84 billion in net income (profit) each year or $2.46 on an earnings per share basis. Novo Nordisk A/S employs 43,258 workers across the globe. View additional information about Novo Nordisk A/S.

What is Novo Nordisk A/S's official website?

The official website for Novo Nordisk A/S is http://www.novonordisk.com/.

How can I contact Novo Nordisk A/S?

Novo Nordisk A/S's mailing address is Novo Alle, Bagsvaerd G7, 2880. The company can be reached via phone at 45-4444-8888 or via email at [email protected]


MarketBeat Community Rating for Novo Nordisk A/S (NYSE NVO)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  344 (Vote Outperform)
Underperform Votes:  447 (Vote Underperform)
Total Votes:  791
MarketBeat's community ratings are surveys of what our community members think about Novo Nordisk A/S and other stocks. Vote "Outperform" if you believe NVO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVO will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: Growth and Income Funds

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel